Transforming Spine Surgery Through Personalized Solutions
Our mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. The Carlsmed aprevo® personalized surgery platform is designed to improve the standard of care for spine surgery one patient at a time.
Our Core Values
We are committed to three guiding principles:
PATIENT-OBSESSED.
DO WHAT IS RIGHT.
ACHIEVE TOGETHER.
Executive Team and Board of Directors
Mike Cordonnier is Chair of the Board of Directors, Chief Executive Officer, and Co-Founder of Carlsmed.
With more than two decades of leadership experience introducing groundbreaking medical technologies, Mike has guided teams across both private and public organizations, including NuVasive, Ellipse Technologies, Zimmer Biomet, Orchid Orthopedics, and X-Spine Systems.
He holds a Bachelor of Science degree in Mechanical Engineering from the University of Dayton.
Niall Casey serves on Carlsmed’s Board of Directors and is the company’s Chief Intellectual Property Officer and Co-Founder.
A seasoned professional in the spine industry, Niall brings deep expertise from technology leadership roles at Alphatec Spine, Ellipse Technologies, NuVasive, and Johnson & Johnson DePuy Synthes Spine.
He holds a J.D. from Suffolk University, and M.S. and B.S. degrees in Biomedical Engineering from Case Western Reserve University.
Richard Heppenstall is Chief Financial Officer and Corporate Treasurer of Carlsmed.
With nearly 30 years of experience, Richard is a seasoned healthcare and medical technology executive who has led finance, strategy, operations, and corporate development across high-growth and global MedTech organizations.
Richard most recently served as Executive Vice President, Chief Financial Officer and Treasurer of ZimVie Inc., a publicly traded medical technology company focused on spine and dental solutions. He joined ZimVie as CFO during its formation as an independent public company following its separation from Zimmer Biomet, helping lead the organization through the transition from a business within a large global medical device company to a standalone enterprise.
Prior to ZimVie, Richard held numerous positions including Chief Financial Officer of Breg, Inc., Senior Vice President of Finance and Treasury at Orthofix Medical, and senior finance and business leadership positions with Solera Holdings, Flowserve Corporation, and CooperVision.
Richard holds an MBA from Santa Clara University and a B.A. in Economics from the University of California, Irvine.
Jennifer Kamocsay is Chief Legal Officer and Secretary of the Board of Directors of Carlsmed.
She brings extensive legal expertise to Carlsmed, with a proven record of advising public life sciences and technology companies on complex corporate and regulatory matters. Prior to joining Carlsmed, she served as the Chief Legal Officer of Akoya Biosciences and held senior legal roles at Rubius Therapeutics and Progress Software Corporation.
Jennifer began her legal career at Skadden, Arps, Slate, Meagher & Flom LLP, representing biotechnology, pharmaceutical, and technology clients in the areas of mergers and acquisitions, securities law and corporate governance. She holds a J.D. from Northeastern University School of Law and a B.A. in History from UCLA.
Jeff Bertolini is the Chief Operating Officer at Carlsmed.
With more than 30 years of experience in the medical device industry, Jeff has held leadership roles across Operations, Information Technology, Sales Operations, and corporate strategy. Prior to joining Carlsmed, he served in key positions at U.S. Surgical Corporation, SpineWave, and NuVasive.
Jeff completed the Chief Technology Officer (CTO) Program at the Wharton School of the University of Pennsylvania. He holds an MBA from Rensselaer Polytechnic Institute and a Bachelor of Science in Operations and Materials Management from Arizona State University.
Scott Durall is the Chief Commercial Officer at Carlsmed.
With more than 30 years of experience in the medical device industry, Scott has held leadership roles across sales, marketing, and corporate strategy. His career includes successful tenures at U.S. Surgical Corporation, Boston Scientific Corporation, and NuVasive.
Scott holds a Bachelor of Business Administration in Marketing from the University of Kentucky.
Sharon Schulzki is the Chief Clinical & Market Access Officer at Carlsmed.
Sharon’s extensive professional journey includes senior leadership roles in marketing and surgical affairs at prominent companies such as J&J and Stryker. She has also played crucial C-suite roles at successful startup ventures, namely Micropore Biosurgery, N-Spine, and Tissue Regeneration Systems, all of which achieved successful exits.
Sharon holds a Bachelor of Science degree in Medical Technology from Loyola University Maryland.
Anthony Jarc serves as the Chief Product and AI Officer at Carlsmed.
With over a decade of leadership experience driving digital transformation and AI innovation in surgical technology, Anthony is dedicated to advancing AI-driven healthcare solutions that enhance surgical performance and optimize patient care.
Anthony joins Carlsmed after working as VP of Digital Products and ML Insights at Intuitive, where he led the strategy and development of AI-enabled solutions that support surgeons in improving patient outcomes.
Anthony holds a B.S. in Mechanical Engineering from Cornell University and a Ph.D. in Biomedical Engineering from Northwestern University, where his research focused on restoring movement, following spinal cord injury.
Julie Lamothe is the Senior Vice President, Quality & Regulatory Affairs at Carlsmed.
She brings over 15 years of experience in the medical industry, including more than a decade focused on spine technologies. Julie’s deep expertise in microbiology, industrial sterilization, and biocompatibility helps ensure the safety and compliance of Carlsmed’s products across global markets.
Julie holds a Ph.D. in Microbiology and Immunology and an MBA from the Rady School of Management at UC San Diego — a unique blend of scientific depth and strategic leadership that drives regulatory excellence at Carlsmed.
Paving the Way for the Future of Spinal Fusion Surgery
First company to receive FDA Breakthrough Device Designation for Intervertebral Spine Fusion Technology
